The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis

. Author manuscript; available in PMC: 2021 Aug 4.

Published in final edited form as: Cancer Prev Res (Phila). 2021 May 26;14(8):811–822. doi: 10.1158/1940-6207.CAPR-20-0620

Figure 1. Incremental outcomes for risk-stratification (based on a mean screening start age of 60), compared to screening start age of 60 for the entire population. Incremental net monetary benefit is based on a cost-effectiveness threshold of £20,000/QALY.